Study Objective

To identify polycystic ovarian syndrome (PCOS) in a population of female patients with McCune−Albright syndrome (MAS) by retrospective chart review.

Design

Retrospective study.

Setting

Academic setting.

Participants

All female patients with a prior diagnosis of MAS who were more than 12 years of age at the time of chart review. Only complete medical records from January 2009 to January 2020 were included in the analysis.

Interventions

None.

Main Outcome Measure(s)

Diagnosis of PCOS based on the Rotterdam 2003 criteria.

Results

Seventeen female patients with MAS were included in the analysis. PCOS appeared to be more prevalent in MAS patients than expected based on population estimates (exact binomial test = 0.353; CI = 0.142-0.617, P = .01). The average body mass index was not significantly different between MAS patients with and without PCOS (23.38 kg/m² vs 23.44 kg/m², 2-sample Wilcoxon rank-sum test with continuity correction, W = 29, P = 0.733). The majority of patients (71%) were treated with an aromatase inhibitor and/or a gonadotropin-releasing hormone (GnRH) agonist.

Conclusions

The results of this study suggest that female individuals with MAS have a statistically higher prevalence of PCOS. These findings warrant further studies to determine whether the increased risk of PCOS may be associated with precocious puberty, treatment of precocious puberty, or other factors.

中文翻译：

---

McCune Albright 综合征患者多囊卵巢综合征的患病率

学习目标

通过回顾性图表审查来识别患有 McCune-Albright 综合征 (MAS) 的女性患者群体中的多囊卵巢综合征 (PCOS)。

设计

回顾性研究。

环境

学术环境。

参加者

所有先前诊断为 MAS 的女性患者，在检查图表时年龄超过 12 岁。分析中仅包含 2009 年 1 月至 2020 年 1 月的完整病历。

干预措施

没有任何。

主要观察指标）

基于鹿特丹 2003 标准的 PCOS 诊断。

结果

17 名患有 MAS 的女性患者被纳入分析。PCOS 在 MAS 患者中的患病率似乎高于基于人口估计的预期（精确二项式检验 = 0.353；CI = 0.142-0.617，P  = .01）。患有和不患有 PCOS 的 MAS 患者的平均体重指数没有显着差异（23.38 kg/m ²与 23.44 kg/m ²，具有连续性校正的 2 样本 Wilcoxon 秩和检验，W = 29，P  = 0.733）。大多数患者 (71%) 接受芳香化酶抑制剂和/或促性腺激素释放激素 (GnRH) 激动剂治疗。

结论

这项研究的结果表明，患有 MAS 的女性个体患 PCOS 的患病率在统计学上更高。这些发现值得进一步研究，以确定 PCOS 风险增加是否与性早熟、性早熟治疗或其他因素有关。